NASDAQ: IMVT · Life Sciences · 8 alerts · CIK 1764013
Share price
$33.28Close, Nov 16
Market cap
$6.89B
Shares outstanding
206.95MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Immunovant, Inc. filings on SEC EDGAR ↗
Immunovant Insider Atul Pande Sells $108K of Stock
Atul Pande sold 3,000 shares of Immunovant, Inc. at $36.00 a share, worth $108K in total on Nov 11, 2026. Shares held after the trade: 116,731 (-2.5%).
Immunovant reported a net loss of $97.2 million for the quarter ended September 30, 2026, compared to $126.5 million in the prior year period. The company maintained a strong liquidity position with $722.3 million in cash and cash equivalents, while research and development expenses remained the primary driver of operating costs at $85.0 million for the quarter.
Immunovant reported financial results for its fiscal second quarter ended September 30, 2026, and announced positive topline data from a potentially registrational trial of IMVT-1402 in rheumatoid arthritis. The company ended the quarter with $722.3 million in cash and cash equivalents, which it expects will fund operations into 2028.
Tiago Girao, CFO, sold 6,606 shares of Immunovant, Inc. at $28.50 a share, worth $188K in total on Oct 28, 2026. Shares held after the trade: 234,192 (-2.7%).